Immunotherapy in breast cancer: Current status and future directions
Author:
Publisher
Elsevier
Reference240 articles.
1. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A;Adams;Journal of Clinical Oncology,2017
2. The peripheral generation of CD4+ CD25+ regulatory T cells;Akbar;Immunology,2003
3. Breast cancer survival rates;American Cancer Society,2017
4. Cancer facts and figures;American Cancer Society,2018
5. Tim-3: An emerging target in the cancer immunotherapy landscape;Anderson;Cancer Immunology Research,2014
Cited by 83 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Biogenic nanoparticles: pioneering a new era in breast cancer therapeutics—a comprehensive review;Discover Nano;2024-08-03
2. Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells;Cancer Letters;2024-08
3. NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors;Cancer Letters;2024-08
4. Novel HER2-based multi-epitope vaccine (HER2-MEV) against HER2-positive breast cancer: In silico design and validation;Human Immunology;2024-07
5. Prognostic Value and Immune Signatures of Anoikis-related Genes in Breast Cancer;Journal of Immunotherapy;2024-06-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3